Leukemia is a cancer of the most primitive cells in the bone marrow, the stem cells.

The main leukemias are:
-Acute lymphoblastic leukemia (ALL) – is the most common type of leukemia in pediatric age. ALL starts in the bone marrow, and most of the time, the leukemic cells invade the blood fairly quickly but can also spread to other parts of the body. 
-Acute myeloid leukemia (AML) – affects both adults and children. It results from the malignant transformation and uncontrolled proliferation of an abnormally differentiated long-lived myeloid progenitor cell resulting in high circulating numbers of immature blood cells and replacement of the bone marrow with malignant cells.
-Chronic lymphoid leukemia (CLL) – mainly affects older adults and and accounts for about a third of all leukemias. It is a type of leukemia that starts in the white blood cells in the bone marrow.
-Chronic myeloid leukemia (CML) – mainly affects adults and does not affect children. Occurs when the pluripotent stem cell undergoes malignant transformation and clonal myeloproliferation, causing overproduction of immature granulocytes.

The ALL is the most common type of acute leukemia in the pediatric population and is responsible for the majority of cancer deaths in children. This type of leukemia varies with age and affects 20%-30% of children with cancer, representing approximately 25% of diagnoses in children under 15 years of age.

AML is a highly heterogeneous disease, presenting as de novo or secondary disease, therapy-related or post-antigenic hematologic disorder. The incidence of disease onset increases with age, with the median age at diagnosis of AML being 67 years, with approximately one-third diagnosed over the age of 75. Conventional therapy for acute myeloid leukemia consists of induction of remission with cytarabine and anthracycline-containing regimens, followed by consolidation therapy, including allogeneic stem cell transplantation, to prolong remission. In recent years, there has been a greater understanding of the pathophysiology of AML, which has facilitated the development of new molecularly targeted therapies and the implementation of a personalized, risk-adapted approach to treatment.

Leukemia Studies


Leukemia Studies


There are several studies available, here are some of the ones you can find:

Status Study Conditions Interventions Locations
Recruiting Physical Activity Adapted at Home Supervised by Videoconferencing in Post-cancer for Children / AYA Treated for Leukemia (ONCOPED SAPATIC)  Leukemia Other: Physical Activity Adapted program CHU de Montpellier
Montpellier, France
Recruiting Long-term Safety Study of Arsenic Trioxide in Newly Diagnosed, Low-to-intermediate Risk Acute Promyelocytic Leukemia Acute Promyelocytic Leukemia Drug: Arsenic Trioxide
  • Ss. Antonio E Biagio E C. Arrigo – Alessandria – Soc Ematologia
    Alessandria, Italy;
  • UO Ematologia con trapianto-Universita’ degli Studi di Bari Aldo Moro
    Bari, Italy;
  • Azienda Ospedaliera – Papa Giovanni XXIII
    Bergamo, Italy
Unknown Phase III Trial in Acute Promyelocytic Leukemia Patients Leukemia
  • Drug: arsenic trioxide;
  • Drug: idarubicin
  • Drug: mercaptopurine
  • Universitätsklinik Innsbruck Hämatologie Onkologie
    Innsbruck, Austria;
  • Krankenhaus der Barmherzigen Schwestern Linz
    Linz, Austria;
  • Universitätsklinik für Innere Medizin III Salzburg
    Salzburg, Austria
Recruiting Understanding Chronic Lymphocytic Leukemia Chronic Lymphocytic Leukemia Dana Farber Cancer Institute
Boston, Massachusetts, United States
Recruiting  Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia Acute Promyelocytic Leukemia Drug: Arsenic trioxide
Drug: Idarubicin
Drug: Cytarabine
(and 4 more…)
French-Belgian-Swiss APL study group
Multiple Locations, France
AML-CG study group
Multiple Locations, Germany
AML-SG study group
Multiple Locations, Germany
(and 5 more…)
Unknown  CAR-T Cell, B-cell Acute Lymphoblastic Leukemia (TriCAR) Leukemia, B-Cell
  • Genetic: Autologous TriCAR T-cells and lymphodepletion chemotherapy
Houston Methodist Hospital
Houston, Texas, United States
Texas Children’s Hospital
Houston, Texas, United States
Recruiting Next Generation Sequencing (NGS) in Familial Acute Myeloid Leukemia and Myelodisplastic Syndromes  Leukemia Genetic: Analysis with molecular biology Chair of Hematology and Bone marrow Transplant Unit
Brescia, Italy
Recruiting First in Human Testing of Dose-escalation of SAR440234 in Patients With Acute Myeloid Leukemia, Acute Lymphoid Leukemia and Myelodysplastic Syndrome Leukemia Drug: SAR440234
  • Investigational Site Number 8400001
    Houston, Texas, United States;
  • Investigational Site Number 2500001
    Paris Cedex 10, France;
  • Investigational Site Number 2500003
    Villejuif Cedex, France
Unknown Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Acute Promyelocytic Leukemia  Leukemia
  • Drug: busulfan;
  • Drug: cyclophosphamide;
  • Drug: cytarabine;
  • (and 10 more…)
  • Innsbruck Universitaetsklinik
    Innsbruck, Austria;
  • Algemeen Ziekenhuis Middelheim
    Antwerp, Belgium;
  • (and 69 more…)
Unknown Imatinib Mesylate With or Without Hydroxychloroquine in Treating Patients With Chronic Myeloid Leukemia Leukemia
  • Drug: hydroxychloroquine;
  • Drug: imatinib mesylate;
  • Genetic: cytogenetic analysis;
  • (and 3 more…)
  • Royal Liverpool University Hospital
    Liverpool, England, United Kingdom;
  • Imperial College London
    London, England, United Kingdom;
  • Gartnavel General Hospital
    Glasgow, Scotland, United Kingdom

New Breathe


New Breathe




Call us now if you are in a medical emergency need, we will reply swiftly and provide you with a medical aid.

2021 © New Breathe. Powered with by Goweb Agency.

2021 © New Breath. Powered with by Goweb Agency.